Molecular epidemiological survey of the quinolone- and carbapenem-resistant genotype and its association with the type III secretion system in pseudomonas aeruginosa

Journal of Medical Microbiology

Volumn 64, Issue 3, 2015, Pages 262-271

  Ferreira, Melina Lorraine ^a   Dantas, Raquel Cavalcanti ^a   Faria, Ana Luiza Souza ^a   Gonçalves, Iara Rossi ^a   De Brito, Cristiane Silveira ^a   Queiroz, Lícia Ludendorff ^a   Gontijo Filho, Paulo P ^a   Ribas, Rosineide Marques ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; ISOLEUCINE; LEVOFLOXACIN; MEROPENEM; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN B; QUINOLONE DERIVATIVE; THREONINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; VIRULENCE FACTOR;

ADULT; ALGD GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLAGIM GENE; BLAIMP GENE; BLASIM GENE; BLASPM GENE; BLAVIM GENE; EXOS GENE; EXOT GENE; EXOU GENE; EXOY GENE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LASB GENE; MAJOR CLINICAL STUDY; MALE; METALLO BETA LACTAMASE GENE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUINOLONE RESISTANCEDETERMINING REGION GENE; TOXA GENE; TYPE III SECRETION SYSTEM; VENTILATOR ASSOCIATED PNEUMONIA; VIRULENCE FACTOR GENE; ADOLESCENT; AGED; BACTERIAL SECRETION SYSTEM; BRAZIL; CHILD; COHORT ANALYSIS; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; INFANT; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MICROBIOLOGY; NEWBORN; PHYSIOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; PRESCHOOL CHILD; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL SECRETION SYSTEMS; BRAZIL; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84923647722     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000023     Document Type: Article

References (51)

1. Aldred, K. J., Kerns, R. J. & Osheroff, N. (2014). Mechanism of quinolone action and resistance. Biochemistry 53, 1565–1574.
2. Andrade, S. S., Sader, H. S., Jones, R. N., Pereira, A. S., Pignatari, A. C. & Gales, A. C. (2006). Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? Mem Inst Oswaldo Cruz 101, 741–748.
3. Bassi, G. L., Ferrer, M., Saucedo, L. M. & Torres, A. (2010). Do guidelines change outcomes in ventilator-associated pneumonia? Curr Opin Infect Dis 23, 171–177.
4. Baumgart, A. M., Molinari, M. A. & Silveira, A. C. (2010). Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14, 433–436.
5. Bleves, S., Viarre, V., Salacha, R., Michel, G. P., Filloux, A. & Voulhoux, R. (2010). Protein secretion systems in Pseudomonas aeruginosa: a wealth of pathogenic weapons. Int J Med Microbiol 300, 534–543.
6. Breidenstein, E. B., de la Fuente-Núñez, C. & Hancock, R. E. (2011). Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19, 419–426.
7. CDC (2002). Guidelines for the prevention of intravascular catheter–related infections. MMWR Morb Mortal Wkly Rep 51, 1–36.
8. CLSI (2014). Performance Standards for Antimicrobial Susceptibility Testing; Document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute.
9. Davis, K. A. (2006). Ventilator-associated pneumonia: a review. J Intensive Care Med 21, 211–226.
10. Edwards, J. R., Peterson, K. D., Andrus, M. L., Tolson, J. S., Goulding, J. S., Dudeck, M. A., Mincey, R. B., Pollock, D. A., Horan, T. C. & NHSN Facilities (2007). National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. Am J Infect Control 35, 290–301.
11. El-Solh, A. A., Hattemer, A., Hauser, A. R., Alhajhusain, A. & Vora, H. (2012). Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 40, 1157–1163.
12. Feltman, H., Schulert, G., Khan, S., Jain, M., Peterson, L. & Hauser, A. R. (2001). Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147, 2659–2669.
13. Franco, M. R., Caiaffa-Filho, H. H., Burattini, M. N. & Rossi, F. (2010). Metallo-b-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital. Clinics (Sao Paulo) 65, 825–829.
14. Galán, J. E. & Collmer, A. (1999). Type III secretion machines: bacterial devices for protein delivery into host cells. Science 284, 1322–1328.
15. Galé s, A. C., Menezes, L. C., Silbert, S. & Sader, H. S. (2003). Dissemination in distinct Brazilian regions of an epidemic carbapenem- resistant Pseudomonas aeruginosa producing SPM metallo-blactamase. J Antimicrob Chemother 52, 699–702.
16. Garey, K. W., Vo, Q. P., Larocco, M. T., Gentry, L. O. & Tam, V. H. (2008). Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 20, 714–720.
17. Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C. & Hughes, J. M. (1996). CDC definitions for nosocomial infections. In APIC Infection Control and Applied Epidemiology: Principles and Practice, pp. A1–A20.Edited by R. N. Olmsted. St Louis: Mosby.
18. Gasink, L. B., Fishman, N. O., Weiner, M. G., Nachamkin, I., Bilker, W. B. & Lautenbach, E. (2006). Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 119, 526.e19–526.e25.
19. Gilbert, D. N., Moellering, R. C., Eliopoulos, G. M. & Sande, M. A. (2007). The Sanford Guide to Antimicrobial Therapy, 37th edn. Sperryville, VA: Antimicrobial Therapy.
20. Golovkine, G., Faudry, E., Bouillot, S., Voulhoux, R., Attré e, I. & Huber, P. (2014). VE-cadherin cleavage by LasB protease from Pseudomonas aeruginosa facilitates type III secretion system toxicity in endothelial cells. PLoS Pathog 10, e1003939.
21. Gupta, A., Kapil, A., Lodha, R., Kabra, S. K., Sood, S., Dhawan, B., Das, B. K. & Sreenivas, V. (2011). Burden of healthcare-associated infections in a paediatric intensive care unit of a developing country: a single centre experience using active surveillance. J Hosp Infect 78, 323–326.
22. Hauser, A. R. (2009). The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7, 654–665.
23. Higgins, P. G., Fluit, A. C., Milatovic, D., Verhoef, J. & Schmitz, F. J. (2003). Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 21, 409–413.
24. Hsu, D. I., Okamoto, M. P., Murthy, R. & Wong-Beringer, A. (2005). Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55, 535–541.
25. Jabalameli, F., Mirsalehian, A., Khoramian, B., Aligholi, M., Khoramrooz, S. S., Asadollahi, P., Taherikalani, M. & Emaneini, M. (2012). Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients. Burns 38, 1192–1197.
26. Kang, C. I., Kim, S. H., Park, W. B., Lee, K. D., Kim, H. B., Kim, E. C., Oh, M. D. & Choe, K. W. (2005). Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49, 760–766.
27. Lanotte, P., Watt, S., Mereghetti, L., Dartiguelongue, N., Rastegar- Lari, A., Goudeau, A. & Quentin, R. (2004). Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J Med Microbiol 53, 73–81.
28. Lee, J. K., Lee, Y. S., Park, Y. K. & Kim, B. S. (2005). Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 25, 290–295.
29. Lodise, T. P., Jr, Patel, N., Kwa, A., Graves, J., Furuno, J. P., Graffunder, E., Lomaestro, B. & McGregor, J. C. (2007). Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51, 3510–3515.
30. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G. & other authors (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18, 268–281.
31. Morales, E., Cots, F., Sala, M., Comas, M., Belvis, F., Riu, M., Salvadó, M., Grau, S., Horcajada, J. P. & other authors (2012). Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res 12, 122–129.
32. Moreira, M. R., Guimarães, M. P., Rodrigues, A. A. A. & Gontijo Filho, P. P. (2013). Antimicrobial use, incidence, etiology and resistance patterns in bacteria causing ventilator-associated pneumonia in a clinical-surgical intensive care unit. Rev Soc Bras Med Trop 46, 39–44.
33. Mouneimné, H., Robert, J., Jarlier, V. & Cambau, E. (1999). Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 43, 62–66.
34. Needham, D. M., Scales, D. C., Laupacis, A. & Pronovost, P. J. (2005). A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 20, 12–19.
35. Park, D. R. (2005). The microbiology of ventilator-associated pneumonia. Respir Care 50, 742–763, discussion 763–765.
36. Peleg, A. Y. & Hooper, D. C. (2010). Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med 362, 1804–1813.
37. Porto, J. P., Santos, R. O., Gontijo Filho, P. P. & Ribas, R. M. (2013). Active surveillance to determine the impact of methicillin resistance on mortality in patients with bacteremia and influences of the use of antibiotics on the development of MRSA infection. Rev Soc Bras Med Trop 46, 713–718.
38. Rello, J., Allegri, C., Rodriguez, A., Vidaur, L., Sirgo, G., Gomez, F., Agbaht, K., Pobo, A. & Diaz, E. (2006). Risk factors for ventilatorassociated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposure. Anesthesiology 105, 709–714.
39. Roberts, R. R., Scott, R. D., II, Hota, B., Kampe, L. M., Abbasi, F., Schabowski, S., Ahmad, I., Ciavarella, G. G., Cordell, R. & other authors (2010). Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods. Med Care 48, 1026–1035.
40. Rosenthal, V. D., Maki, D. G., Salomao, R., Moreno, C. A., Mehta, Y., Higuera, F., Cuellar, L. E., Arikan, O. A., Abouqal, R., Leblebicioglu, H. & International Nosocomial Infection Control Consortium (2006). Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 145, 582–591.
41. Roy-Burman, A., Savel, R. H., Racine, S., Swanson, B. L., Revadigar, N. S., Fujimoto, J., Sawa, T., Frank, D. W. & Wiener-Kronish, J. P. (2001). Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183, 1767–1774.
42. Sader, H. S., Gales, A. C., Pfaller, M A.,Mendes, R. E., Zoccoli, C., Barth, A. & Jones, R. N. (2001). Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 5, 200–214.
43. Sader, H. S., Reis, A. O., Silbert, S. & Gales, A. C. (2005). IMPs, VIMs and SPMs: the diversity of metallo-b-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital. Clin Microbiol Infect 11, 73–76.
44. Suárez, C., Peña, C., Gavaldá, L., Tubau, F., Manzur, A., Dominguez, M. A., Pujol, M., Gudiol, F. & Ariza, J. (2010). Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int J Infect Dis 14 (Suppl. 3), e73–e78.
45. Van der Bij, A. K., Van Mansfeld, R., Peirano, G., Goessens, W. H., Severin, J. A., Pitout, J. D., Willems, R. & Van Westreenen, M. (2011). First outbreak of VIM-2 metallo-b-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes. Int J Antimicrob Agents 37, 513–518.
46. Van der Bij, A. K., Van der Zwan, D., Peirano, G., Severin, J. A., Pitout, J. D., Van Westreenen, M., Goessens, W. H. & MBL-PA Surveillance Study Group (2012). Metallo-b-lactamase-producing Pseudomonas aeruginosa in the Netherlands: the nationwide emergence of a single sequence type. Clin Microbiol Infect 18, E369–E372.
47. Voor In’t Holt A. F, Severin, J. A, Lesaffre, E. M. & Vos, M. C. (2014). A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 58, 2626–2637.
48. Wareham, D. W. & Curtis, M. A. (2007). A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. Int J Med Microbiol 297, 227–234.
49. Wong-Beringer, A., Wiener-Kronish, J., Lynch, S. & Flanagan, J. (2008). Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 14, 330–336.
50. Woodford, N. (2010). Rapid characterization of b-lactamases by multiplex PCR. Methods Mol Biol 642, 181–192.
51. Zilberberg, M. D. & Shorr, A. F. (2010). Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis 51 (Suppl. 1), S131–S135.